Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Verici Dx Plc ( (GB:VRCI) ) is now available.
Verici Dx Plc has announced significant progress in the adoption of its Tutivia™ test, aimed at detecting acute rejection in transplant patients. The company has onboarded nine new transplant centers in Q3, bringing the total to 30 centers, which account for 16% of annual transplants in the US. Additionally, there has been a 19% increase in ordering clinicians, indicating strong commercial momentum. The company has also expanded its commercial team with new senior sales hires and a Director of Clinical Partnerships, positioning itself to meet market expectations for the full year.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Spark’s Take on GB:VRCI Stock
According to Spark, TipRanks’ AI Analyst, GB:VRCI is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including ongoing losses and negative cash flows. Technical analysis provides some short-term positive signals, but valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:VRCI stock, click here.
More about Verici Dx Plc
Verici Dx Plc is a company specializing in advanced clinical diagnostics, particularly for organ transplants. Their primary product, the Tutivia™ test, is designed to detect acute rejection in transplant patients, with a focus on expanding its adoption across transplant centers in the United States.
Average Trading Volume: 2,953,868
Technical Sentiment Signal: Sell
Current Market Cap: £9.84M
For a thorough assessment of VRCI stock, go to TipRanks’ Stock Analysis page.